The Genomenon team was thrilled with the response to last week’s webinar, Prognosis and Potential: How POLE and PIK3R1 Are Changing How We Approach Endometrial Cancer, with guest speakers from Intermountain Health. The recording is now available to watch, revisit, and share.Watch variant scientists Aneesa Al-Sadooni, PhD, and Natalie Peer, PhD, to learn how biochemical and clinical trial research may shed light on the impacts of PIK3R1 mutations in endometrial cancers, and how the detection of a POLE mutation can spare patients the toxicity of overtreatment.
Are you confident that you have all the evidence you need for variant interpretation?Getting started with Mastermind takes seconds, and you’ll start with a complimentary trial of the Professional Edition. Sign up today and start searching.About Genomenon
Genomenon is an AI-driven genomics company focused on making genomic information actionable for patients with rare genetic diseases and cancer. Keeping pace with the ever-evolving body of knowledge within genomics, Genomenon connects current research with patient DNA to accelerate clinical decision-making and pharmaceutical drug discovery.
Learn more about Genomenon at genomenon.com and follow them on LinkedIn and Twitter.
